T-Cypher Bio
UK - OxfordBiotechnology
Focus: T-Cypher Bio is a newly founded (2024) UK-based biotechnology company specializing in T-cell receptor (TCR)-based therapeutics for oncology. The company is publicly listed but remains in early-stage development with no disclosed commercial products or pipeline programs.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at T-Cypher Bio?
AI assessmentT-Cypher Bio represents a speculative, early-stage bet on TCR technology with significant execution risk and minimal operational visibility; suitable only for risk-tolerant early-stage biotech operators.
Why Work Here
- Early-stage opportunity in TCR therapeutics, a differentiated immunotherapy modality with significant unmet potential in oncology
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for T-Cypher Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.